Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
By Amy Stulick
Skilled Nursing News
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector.
As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
On Tuesday, federal policy makers released the names of the first 10 drugs approved to be part of Medicare’s first-ever price negotiations in order to further the goals of the Inflation Reduction Act.
Certain blood thinners, diabetes treatments and medications used for COPD, cancer, heart failure, cardiovascular disease and psoriatic arthritis covered under Medicare Part D will be under price negotiations starting on Jan. 1, 2026.
Such drugs have a high expenditure, and are single source drugs without generic or biosimilar competition. Many have been on the U.S. market for an average of 13 years, according to ATI Advisory.
“Long-term care patients and pharmacies will be severely and disproportionately impacted by these price negotiations, given that eight of the medications named by the Biden administration are heavily prescribed to patients in long-term care facilities,” Alan Rosenbloom, president and CEO of SCPC, said in a statement.
Read the full original article here.
Recent Posts
-
Senior Care Pharmacy Coalition Welcomes New Vice President of Strategy and Government Affairs
The Senior Care Pharmacy Coalition (SCPC), the leading voice for the nation’s long-term care (LTC) pharmacy community, announced today the hiring of Shara Selonick (formerly Shara Siegel) as Vice President of Strategy and Government Affairs. Selonick will work closely with the organization’s leadership and board of directors to drive advocacy and policy initiatives on behalf of the LTC pharmacy sector.
-
SCPC Comments on 2028 IPAY Draft Guidance
June 25, 2025 The Honorable Chris KlompDeputy Administrator and Director of the Center for MedicareCenters for Medicare & Medicaid ServicesDepartment of Health and Human Services7500 Security BoulevardBaltimore, MD 21244 Re: Medicare Drug Price Negotiation Program Draft Guidance Dear Deputy Administrator Klomp: On behalf of the Senior Care Pharmacy Coalition (SCPC), we write to comment on […]
-
SCPC Urges Congress to Include LTC Pharmacy Fix in Reconciliation Package to Save Prescription Drug Access for Seniors in Long-Term Care
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement regarding the reconciliation package passed by the House Energy and Commerce Committee on May 14.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.